The potential usefulness of sputum cytology in the conclusive diagnosis of methotrexate-associated lymphoproliferative disorders: A case report

Seiya Mizuguchi1, Kenichi Mizutani2, Manabu Yamashita1, Hiroshi Minato3 and Sohsuke Yamada2

Abstract

Background: Methotrexate has been used as an anchor drug for the treatment of rheumatoid arthritis and is considered to be a cause of methotrexate-associated lymphoproliferative disorder. Spontaneous regression can occur after withdrawal of methotrexate and may be associated with Epstein–Barr virus positivity and non-diffuse large B cell lymphoma histological type. Methotrexate-associated lymphoproliferative disorders are often diagnosed pathologically by lung biopsy. To the best of our knowledge, there have been no studies on the cytological diagnosis of methotrexate-associated lymphoproliferative disorder using sputum smears.

Case: A 70-year-old man, who was diagnosed with rheumatoid arthritis 13 years previously and who had been treated with methotrexate, presented shortness of breath and productive cough. Methotrexate-associated lymphoproliferative disorder was suspected as the sputum cytology showed many atypical lymphoid cells with hyperchromatic enlarged nuclei, foamy cytoplasm and distinct nucleoli. Chest computed tomography revealed multiple nodular shadows with interstitial pneumonia in the bilateral lower lung field. A lung biopsy specimen contained atypical lymphoid cells that were immunohistochemically positive for CD20 and MUM-1, and weakly positive for bcl-6, but negative for CD3 and CD10. There were no Epstein–Barr virus-infectious lymphoid cells by ISH-EBER. He was finally diagnosed with methotrexate-associated lymphoproliferative disorder (non-germinal center B-cell-like diffuse large B cell lymphoma histological type). Most of the nodules disappeared spontaneously following the withdrawal of methotrexate.

Discussion and conclusion: A cytologically conclusive diagnosis of methotrexate-associated lymphoproliferative disorder may be reached using sputum smears and clinical information.

Keywords
Methotrexate-associated lymphoproliferative disorders, sputum

Date received: 17 September 2018; accepted: 13 February 2019
specimens. To the best of our knowledge, no studied have been reported on the cytological diagnosis of MTX-LPD using sputum smears.

Case

A 70-year-old man, who had been diagnosed with RA 13 years previously and who have been treated with 6 mg MTX per week and 1.5 mg tacrolimus per day, presented shortness of breath and productive cough. Before the presentation, RA was controlled well without any symptoms such as arthritis, which could mean that activity of the disease was low. There were no other clinical symptoms such as fever up. A blood test showed high C-reactive protein (1.32 mg/dL), Lactate Dehydrogenase (269 U/L) and soluble interleukin-2 receptor (1860 U/mL) levels. EBV antibody tests confirmed prior infection. Other results of blood test were as follows: red blood cells (3,910,000/µL), Hb (13.5 g/dL), white blood cells (6300/µL), aspartate aminotransferase (14 U/L), alanine aminotransferase (12 U/L), blood urea nitrogen (15 mg/dL), Cr (0.63 mg/dL). Chest computed tomography revealed multiple nodular shadows with interstitial pneumonia in the bilateral lower lung fields (Figure 1(a), left). Since infectious pneumonia was suspected, sputum cytology was performed. Macroscopically, the sputum was colorless and showed no atypical findings. Necrotic debris was observed in the background of the sputum cytology (Figure 1(b)). The sputum cytology showed many atypical lymphoid cells with low cell connectivity, a high nuclear-to-cytoplasmic (N/C) ratio, foamy cytoplasm, increased chromatin and distinct nucleoli (Figure 1(b) and (c)). Cytomorphologically, reactive lymphoid hyperplasia, lymphoproliferative disorder, adenocarcinoma and neuroendocrine tumor were considered as the differential diagnoses. Bronchoscopy showed protuberating mucosa with vascular proliferation and bleeding tendency. Lung biopsy revealed atypical mid-
large-sized lymphoid cells with a high N/C ratio, cleaved nuclei and distinct nucleoli (Figure 1(d)). Immunohistochemical staining of the lung biopsy specimen showed that the atypical lymphoid cells were positive for CD20 (Figure 2(a)) and MUM-1 (Figure 2(b)), and weakly positive for bcl-6, but negative for CD3 (Figure 2(c)) and CD10. ISH-EBER showed no EBV-infectious lymphoid cells (Figure 2(d)). The patient was finally diagnosed with MTX-LPD (non-germinal center B-cell-like DLBCL histological type). Most of the nodules disappeared spontaneously about 3 weeks after the withdrawal of MTX (Figure 1(a), right); thereafter, only tacrolimus was used. Total follow-up period after MTX withdrawal was 15 months and there is no progression of the disease.

Discussion

In the World Health Organization (WHO) classification of lymphoid neoplasms, MTX-LPDs are categorized as other iatrogenic immunodeficiency-associated lymphoproliferative disorder (OIIA-LPD). Forty percentage of MTX-LPD patients are EBV-positive. Ichikawa et al. reported that approximately 40% of MTX-LPDs occurred at extranodal sites and approximately 19% occurred in the lung. In approximately 83% of RA-LPD patients, the condition was associated with MTX.3

Approximately 55% of MTX-LPD patients were diagnosed with the DLBCL histological type. Spontaneous regression of the lesions occurred in approximately 60% of MTX-LPD patients after the withdrawal of MTX, while progression after MTX withdrawal was observed in approximately 40% of MTX-LPD patients. Spontaneous regression following MTX withdrawal has been associated with EBV positivity and a non-DLBCL histological type of LPD, whereas age >70 years and the DLBCL histological type are associated with shorter survival. In this case, it is interesting that spontaneous regression occurred after the withdrawal of MTX, considering that the patient was 70 years of age, was diagnosed with MTX-LPD (DLBCL histological type) and was EBV negative. No recurrence was reported.

Sensitivity of sputum cytology is highest for detecting squamous cell carcinoma and malignant lymphoma of lung is usually reported on bronchoscopic specimen such as bronchial brushings and washings.4 Moreover, to the best of our knowledge, there are few reports of malignant lymphoma diagnosed by sputum cytology. Although the exact rate is not clear, frequency of malignant lymphoma diagnosed by sputum cytology is probably low.

The cytological, histological and immunohistochemical findings of MTX-LPD are similar to those of malignant lymphoma in non-immunosuppressed hosts; thus, the diagnosis

![Figure 2. Immunohistochemical staining of a lung biopsy specimen showed that the atypical lymphoid cells were positive for CD20 (a) and MUM-1 (b), but negative for CD3 (c). ISH-EBER (d) was negative (original magnification: ×200).](image-url)
of the entity is difficult with cytology alone, and clinical information is necessary. In this case, with low cell cohesive-ness, the atypical cells in the sputum smear were considered to be lymphocytes. Although reactive lymphoid hyperplasia was a differential diagnosis, neoplastic LPD was suspected based on the monotonous proliferation and high nuclear atypia of the cells, and the necrotic background. Cell size and morphology are important criteria in cytological diagnosis of malignant lymphoma. Considering size of atypical cells in sputum specimen in this case, marginal zone lymphoma (mucosa-associated lymphoid tissue (MALT) lymphoma), mantle cell lymphoma and follicular lymphoma are included in differential diagnosis of histological type of MTX-LPD. On the other hand, the most frequent type of MTX-LPD is DLBCL and that of MALT lymphoma, mantle cell lymphoma and follicular lymphoma is very low; therefore, DLBCL is also differential diagnosis. In our case, sputum cytology reported possibility of MTX-LPD and suggested necessity of lung biopsy, which led to diagnosis as DLBCL type. In addition to our case, there have been some previous case reports of patients diagnosed with malignant lymphoma. These patients were diagnosed with Hodgkin lymphoma or Adult T-cell leukemia/lymphoma based on sputum test and immunocytochemistry. Therefore, our case indicates that the diagnosis of MTX-LPD based on sputum cytology is possible.

**Conclusion**

We reported that cytological diagnosis of MTX-LPD was achieved using a sputum smear with clinical information. The early detection of MTX-LPD is considered to be a prognostic factor. Thus, simple and rapid sputum cytology is a useful tool for diagnosing MTX-LPD occurring in the lung. This report shows the potential application of sputum cytology in making a conclusive diagnosis of MTX-LPD without invasive lung biopsy.

**Acknowledgements**

This article is based upon a Presentation at the 56th Annual Autumn Meeting of the Japanese Society of Clinical CytoLOGY, in 2017. The authors thank all of the members of our department. S.M., K.M. and S.Y. participated in the conception of the idea and writing of the manuscript. S.M., K.M., M.Y., H.M. and S.Y. performed the clinical investigation and pathological/immunohistochemical examination. All authors have read and approved the final manuscript.

**Availability of data and materials**

The dataset supporting the findings and conclusions of this case report is included within the article.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Ethics approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Funding**

The author(s) received no financial support for the research, authorship and/or publication of this article.

**Informed consent**

Written informed consent was obtained from the patient for their anonymized information to be published in this article.

**ORCID iDs**

Seiya Mizuguchi https://orcid.org/0000-0002-0636-9058
Kenichi Mizutani https://orcid.org/0000-0003-2742-5693
Sohsuke Yamada https://orcid.org/0000-0003-2662-0024

**References**

1. Steven HS, Elias C, Nancy LH, et al. *WHO classification of tumours of haematopoietic and lymphoid tissues*. Revised 4th ed. Lyon: IARC Press, 2017.
2. Shimizu Y, Nakajima A, Inoue E, et al. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. *Clin Rheumatol* 2017; 36(6): 1237–1245.
3. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. *Eur J Haematol* 2013; 91(1): 20–28.
4. Paolo G, Vijaya B and Shahla M. *Differential diagnosis in cytopathology*. 1st ed. Cambridge: Cambridge University Press, 2010.
5. AbdullGaffar B, Khalid M and Samuel R. Unsuspected Hodgkin lymphoma first diagnosed by sputum cytology. *Diagn Cytopathol* 2011; 39(8): 631–633.
6. Qin J, Liu J and Axiotis CA. Cytological diagnosis of adult T-cell leukemia/lymphoma in sputum. *Diagn Cytopathol* 2016; 44(5): 416–418.